Compare Marsh & McLennan Companies, Inc. (MRSH) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Organon & Co. Common Stock — how do they compare? Marsh & McLennan Companies, Inc. trades at $183.87 (market cap $85.13B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 23.6× Organon & Co. Common Stock's market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.22%). Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Organon & Co. Common Stock for 0 Days on average.
| MRSH | OGN | |
|---|---|---|
Market Cap | $85.13B | $3.61B |
Volume | 2,472,018 | 1,808,049 |
Sector | Financials | Health |
52-Week High | $203.85 | $13.81 |
52-Week Low | $157.32 | $5.70 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $105.82B | $11.03B |
Dividend Yield | 2.22% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $177.01, up 0.27% on the day, with a bullish technical signal and strong fundamentals. The company reported revenue of $26.98 billion in 2025, with net income of $4.16 billion and a net margin of 15.41%. Recent earnings have consistently beaten estimates, and the company completed the acquisition of Accel Holdings in October 2026, signaling growth initiatives. Valuation ratios include a P/E of 21.61 and P/S of 3.09, while analyst consensus price target is $202.71.
The outlook for MRSH is positive, supported by earnings beats and strategic acquisitions, but risks include competitive pressures and potential margin compression. Analyst sentiment is mixed with a 'Hold' consensus, suggesting cautious optimism. The stock offers upside to the price target but faces execution risks in integrating acquisitions and maintaining profitability amid economic uncertainties.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
